Pharmacokinetics and Pharmacodynamics of Febuxostat (TMX‐67), a Non‐Purine Selective Inhibitor of Xanthine Oxidase/Xanthine Dehydrogenase (NPSIXO) in Patients with Gout and/or Hyperuricemia

Autor:	K. Takeda, K. Komoriya, T. Nakachi, J. Kubo, S. Hoshide, H. Kobayashi, H. Yamanaka, M. Tsuchimoto, N. Kamatani
Rok vydání:	2004
Předmět:	Purine Male musculoskeletal diseases Xanthine Oxidase congenital hereditary and neonatal diseases and abnormalities Time Factors Gout Xanthine Dehydrogenase Cmax Hyperuricemia Pharmacology Biochemistry chemistry.chemical_compound Febuxostat Pharmacokinetics Genetics medicine Humans Enzyme Inhibitors skin and connective tissue diseases Xanthine oxidase Chemistry nutritional and metabolic diseases General Medicine medicine.disease Oxygen Thiazoles Xanthine dehydrogenase Area Under Curve Pharmacodynamics Molecular Medicine sense organs medicine.drug
Zdroj:	Nucleosides, Nucleotides and Nucleic Acids. 23:1119-1122
ISSN:	1532-2335 1525-7770
DOI:	10.1081/ncn-200027381
Popis:	The diurnal change of sUA and the effect of febuxostat on this change were investigated in 10 patients with gout and/or hyperuricemia. The diurnal sUA change after the last dose during the 4-week treatment phase (20 mg, QD) was almost the same as the pre-treatment value. Considering the dose, the AUC(obs) and Cmax of unchanged drug in patients with gout and/or hyperuricemia were estimated to be similar to those of healthy male adults. The results show that a 6-week treatment with febuxostat is safe and well-tolerated in the target patient population for this drug.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11ae958d2b1e404836d66b3fc5c9a222 https://doi.org/10.1081/ncn-200027381 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.